BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Santis GC, Oliveira LC, Garibaldi PMM, Almado CEL, Croda J, Arcanjo GGA, Oliveira ÉAF, Tonacio AC, Langhi DM Jr, Bordin JO, Gilio RN, Palma LC, Santos EV, Haddad SK, Prado BPA Jr, Pontelli MC, Gomes R, Miranda CH, Martins MA, Covas DT, Arruda E, Fonseca BAL, Calado RT. High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Emerg Infect Dis 2022;28. [PMID: 35081022 DOI: 10.3201/eid2803.212299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Bartelt LA, Markmann AJ, Nelson B, Keys J, Root H, Henderson HI, Kuruc J, Baker C, Bhowmik DR, Hou YJ, Premkumar L, Cornaby C, Schmitz JL, Weiss S, Park Y, Baric R, de Silva AM, Lachiewicz A, Napravnik S, van Duin D, Margolis DM. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study. mBio 2022;:e0175122. [PMID: 36135380 DOI: 10.1128/mbio.01751-22] [Reference Citation Analysis]
2 Estcourt LJ, Cohn CS, Pagano MB, Iannizzi C, Kreuzberger N, Skoetz N, Allen ES, Bloch EM, Beaudoin G, Casadevall A, Devine DV, Foroutan F, Gniadek TJ, Goel R, Gorlin J, Grossman BJ, Joyner MJ, Metcalf RA, Raval JS, Rice TW, Shaz BH, Vassallo RR, Winters JL, Tobian AAR. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Ann Intern Med 2022. [PMID: 35969859 DOI: 10.7326/M22-1079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Qian Z, Zhang Z, Ma H, Shao S, Kang H, Tong Z. The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials. Front Immunol 2022;13:964398. [DOI: 10.3389/fimmu.2022.964398] [Reference Citation Analysis]
4 Focosi D, Casadevall A. High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Emerg Infect Dis 2022;28:1083. [PMID: 35450567 DOI: 10.3201/eid2805.220191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 De Santis GC, Calado RT. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response). Emerg Infect Dis 2022;28:1083-4. [PMID: 35447061 DOI: 10.3201/eid2805.220363] [Reference Citation Analysis]
6 Deng J, Heybati K, Ramaraju HB, Zhou F, Rayner D, Heybati S. Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis. Infection 2022. [PMID: 35438413 DOI: 10.1007/s15010-022-01825-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, Casadevall A. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clin Microbiol Rev 2022;:e0020021. [PMID: 35262370 DOI: 10.1128/cmr.00200-21] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]